Construction of a Clinical Comprehensive Evaluation and Selection Criteria System for Uric Acid-lowering Drugs in Yunnan Province

OBJECTIVE  To establish a clinical comprehensive evaluation and selection criteria system for uric acid-lowering drugs in Yunnan province, providing a reference basis for the rational use of uric acid-lowering drugs in medical institutions in Yunnan province.

METHODS According to authoritative guidelines and drug instructions, the Delphi expert consultation method was subjected to seek expert opinions and establish an expert consensus on the evaluation and selection scoring criteria of uric acid-lowering drugs in Yunnan Province, and used this scoring criteria to score seven uric acid-lowering drugs.

RESULTS The established criteria system adopted a quantitative scoring approach across 6 dimensions, including effectiveness, safety, economy, suitability, accessibility, and innovation. The total scores from high to low were febuxostat(Ruiyang), benzbromarone(Narcaricin), benzbromarone(Ertongshu), allopurinol(Aomaibili), allopurinol(Juilian), febuxostat(Feburic), and probenecid.

CONCLUSION Guided by clinical value, this study constructed a scientific and standardized “Clinical Comprehensive Evaluation and Selection Criteria System for Uric Acid-lowering Drugs in Yunnan Province”. It provides a scientific basis for the formulation of drug allocation and procurement catalogs in medical institutions of Yunnan province, as well as the rational use of drugs.